University of Birmingham researchers said CD4+ helper T cells can retain obesity-linked epigenetic changes for five to 10 years after weight loss, based on human cohorts and mouse models.
Published in EMBO Reports, the study links this molecular imprint to impaired autophagy, premature immune ageing, persistent inflammation and continued risk of type 2 diabetes, cardiovascular disease and some cancers.
The findings suggest short-term weight loss may not fully restore health, supporting longer-term weight management and possibly therapies such as SGLT2 inhibitors to help reverse immune reprogramming.
Since weight loss isn't a full reset, can new drugs reprogram our immune cells to forget their memory of obesity?
With human trials starting in 2026, could we soon reboot our immune systems to completely erase obesity's long-term damage?
Lasting Immune Dysregulation After Weight Loss: The 5 to 10-Year Epigenetic Legacy of Obesity
Overview
A 2026 study revealed that obesity causes lasting epigenetic changes in CD4+ T cells, which persist for 5 to 10 years after weight loss. These persistent changes impair autophagy and promote immune senescence, leading to chronic low-grade inflammation that increases the risk of type 2 diabetes, cardiovascular disease, and certain cancers long after weight normalization. Treatments like SGLT2 inhibitors can clear senescent cells, reduce inflammation, and enhance autophagy, helping to mitigate this epigenetic memory. Combining these drugs with sustained weight management offers a promising strategy to reduce long-term disease risk, while future therapies may directly reverse the underlying epigenetic marks.